Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer

Botensilimab (BOT) promotes optimized T-cell priming, activation, and memory formation by strengthening antigen-presenting cell/T-cell co-engagement. As a fragment crystallizable (Fc)-enhanced next-generation anticytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, BOT also promotes intratumoral Treg depletion to improve potency while mitigating difficult-to-treat side effects associated with first-generation CTLA-4 therapy. Results from an expanded phase IA/B study (NCT03860272) in patients with recurrent platinum-resistant/refractory ovarian cancer treated with BOT plus balstilimab (BAL; anti-programmed cell death protein 1 [PD-1]) are presented.